<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700813</url>
  </required_header>
  <id_info>
    <org_study_id>2019-166</org_study_id>
    <secondary_id>B707201940651</secondary_id>
    <nct_id>NCT04700813</nct_id>
  </id_info>
  <brief_title>Research Study for Rare Pathogenic Mutations Causing Type 2 Diabetes and Complications</brief_title>
  <acronym>PreciDiag</acronym>
  <official_title>Research Study for Rare Pathogenic Mutations Causing Type 2 Diabetes and Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EGID, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-center trial The goal is to better understand the various genetic mutations&#xD;
      encountered in cases of type 2 diabetes as well as their frequency of occurrence in the&#xD;
      population.&#xD;
&#xD;
      Such analyzes also make it possible to develop personalized medicine and to be able to&#xD;
      prevent the associated risks.&#xD;
&#xD;
      The aim of this work is also to demonstrate the value of a systematic genetic diagnosis of&#xD;
      patients with DMT2 in order to improve their clinical management.&#xD;
&#xD;
      Taking a blood sample, which will consist of the single sample from the entire study (1&#xD;
      single visit, combined with a follow-up visit to the patient's usual diabetist).&#xD;
&#xD;
      Participation in this study would make it possible to diagnose rare pathogenic mutations in&#xD;
      type 2 diabetes and therefore to be able to adapt the treatment in a specific and personal&#xD;
      way depending on the presence or not of the mutations and also to prevent the appearance of&#xD;
      other pathologies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Procedure and methodology: during a follow-up visit to their usual diabetist (at CHU de&#xD;
      Liège), we will send each potential volunteer, fulfilling the conditions for inclusion, an&#xD;
      information and consent form relating to genetic analyzes. Participation in the protocol is&#xD;
      voluntary, after detailed information and discussion with the patient. Once the participation&#xD;
      agreement has been obtained, we will take a blood sample, which will be the only sample from&#xD;
      the entire study.&#xD;
&#xD;
      All the tubes will be centrifuged, decanted, separated and frozen at -80 °C at the CHU de&#xD;
      Liège for constitution of a serum bank on site, and of a DNA library at UMR8199.&#xD;
&#xD;
      For DNA extraction, samples will be sent at -80 ° C. DNA extraction will be automated&#xD;
      (Autopure, Qiagen).&#xD;
&#xD;
      After DNA extraction, the genes involved in monogenic diabetes (Table 1) will be sequenced&#xD;
      via Twist or NimbleGen capture in combination with Illumina sequencing (NovaSeq 6000), as&#xD;
      recommended by Twist, NimbleGen and Illumina. The target will also include genes involved in&#xD;
      the rare forms of metabolic diseases associated with diabetes: obesity, metabolic syndrome,&#xD;
      familial hypercholesterolemia, kidney disease, cardiovascular disease and non-alcoholic fatty&#xD;
      liver disease. This will help refine the patient's phenotypic understanding and improve their&#xD;
      care.&#xD;
&#xD;
      Table 1. List of genes involved in monogenic diabetes&#xD;
&#xD;
      Gene ID NM ID ABCC8 NM_000352.4 APPL1 NM_012096.2 BLK NM_001715.2 CEL NM_001807.4 DNAJC3&#xD;
      NM_006260.4 DYRK1B NM_004714.2 EIF2AK3 NM_004836.5 FOXP3 NM_014009.3 GATA4 NM_002052.3 GATA6&#xD;
      NM_005257.5 GCK NM_000162.3 GLIS3 NM_152629.3 HNF1A NM_000545.5 HNF1B NM_000458.3 HNF4A&#xD;
      NM_175914.4 IER3IP1 NM_016097.4 INS NM_000207.2 KCNJ11 NM_000525.3 KLF11 NM_003597.4 LRBA&#xD;
      NM_6726.4 MAFA NM_201589.3 MNX1 NM_005515.3 MRAP2 NM_138409.3 NEUROD1 NM_002500.4 NEUROG3&#xD;
      NM_020999.3 NKX2-2 NM_002509.3 PAX4 NM_006193.2 PAX6 NM_000280.4 PCBD1 NM_000281.3 PDX1&#xD;
      NM_000209.3 PPP1R15B NM_032833.4 PTF1A NM_178161.2 RFX6 NM_173560.3 SLC19A2 NM_006996.2&#xD;
      SLC2A2 NM_000340.1 STAT3 NM_139276.2 TRMT10A NM_152292.4 WFS1 NM_006005.3 ZFP57&#xD;
      NM_001109809.2&#xD;
&#xD;
      Following sequencing, mutations will be detected and annotated according to the&#xD;
      bioinformatics protocol implemented and optimized in UMR8199 since 2009.&#xD;
&#xD;
      Clinical and medical data will also be collected: weight, height, blood pressure, drug&#xD;
      treatment, medical and surgical history as well as any other important medical information&#xD;
      concerning the subject of the project. Data concerning the patient's ethnic origin will also&#xD;
      be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>pathogenic mutations causing type 2 diabetes</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Diabete Type 2</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>search for rare pathogenic mutations</intervention_name>
    <description>search for rare pathogenic mutations causing diabetes type 2</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  1 × 5mL of blood on EDTA for DNA extraction,&#xD;
&#xD;
        -  4 × 5 mL of blood in a dry tube for the constitution of a serum bank,&#xD;
&#xD;
        -  2 × 5 mL of blood on EDTA for the preservation of the plasma for the subsequent&#xD;
           performance of additional analyzes as part of a positive genetic diagnosis.&#xD;
&#xD;
      Au total : 35 mL de sang seront prélevés.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        type 2 diabetic patients monitored for this pathology at the study site academic hospital&#xD;
        of Liège&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diabetes type 2&#xD;
&#xD;
        Criteria exclusion:&#xD;
&#xD;
          -  Refusal of participation&#xD;
&#xD;
          -  Type 1 diabetic&#xD;
&#xD;
          -  Presence of auto-antibodies directed against the β cells of the pancreas&#xD;
             (insulin-secreting)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolas Paquot</last_name>
    <phone>+323662942</phone>
    <email>nicolas.paquot@chuliege.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Marjorie Fadeur</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Fadeur</last_name>
      <phone>+3243662942</phone>
      <email>marjorie.fadeur@chuliege.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Nicolas PAQUOT</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

